Tata 1mg said it has turned Ebitda positive across all its established businesses in FY26, marking a key profitability milestone for one of India's largest digital healthcare platforms, as it accelerates expansion across pharmacy, diagnostics and speciality care.
The company said its diagnostics business crossed an annualised revenue run rate of more than Rs 600 crore during the year, growing over 40 per cent year-on-year while sustaining double-digit Ebitda margins.
